These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 23270413)
21. Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. Gu F; Hsu HK; Hsu PY; Wu J; Ma Y; Parvin J; Huang TH; Jin VX BMC Syst Biol; 2010 Dec; 4():170. PubMed ID: 21167036 [TBL] [Abstract][Full Text] [Related]
22. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Cun J; Yang Q Biomed Pharmacother; 2018 Nov; 107():117-128. PubMed ID: 30086458 [TBL] [Abstract][Full Text] [Related]
23. Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line. Jayavelu ND; Bar N BMC Genomics; 2015 Dec; 16():1077. PubMed ID: 26763900 [TBL] [Abstract][Full Text] [Related]
24. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310 [TBL] [Abstract][Full Text] [Related]
25. Prioritizing breast cancer subtype related miRNAs using miRNA-mRNA dysregulated relationships extracted from their dual expression profiling. Hua L; Zhou P; Li L; Liu H; Yang Z J Theor Biol; 2013 Aug; 331():1-11. PubMed ID: 23619378 [TBL] [Abstract][Full Text] [Related]
26. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells. Klinge CM; Piell KM; Tooley CS; Rouchka EC Sci Rep; 2019 Jul; 9(1):9430. PubMed ID: 31263129 [TBL] [Abstract][Full Text] [Related]
27. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855 [TBL] [Abstract][Full Text] [Related]
28. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685 [TBL] [Abstract][Full Text] [Related]
29. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer. Xue B; Li S; Jin X; Liu L BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654 [TBL] [Abstract][Full Text] [Related]
30. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143 [TBL] [Abstract][Full Text] [Related]
31. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells. Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806 [TBL] [Abstract][Full Text] [Related]
32. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041 [TBL] [Abstract][Full Text] [Related]
33. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975 [TBL] [Abstract][Full Text] [Related]
34. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer. Han X; Li Q; Liu C; Wang C; Li Y J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849 [TBL] [Abstract][Full Text] [Related]
35. Identifying miRNA-mRNA regulatory relationships in breast cancer with invariant causal prediction. Pham VV; Zhang J; Liu L; Truong B; Xu T; Nguyen TT; Li J; Le TD BMC Bioinformatics; 2019 Mar; 20(1):143. PubMed ID: 30876399 [TBL] [Abstract][Full Text] [Related]
36. miRNA expression patterns in chemoresistant breast cancer tissues. Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164 [TBL] [Abstract][Full Text] [Related]
37. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
38. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025 [TBL] [Abstract][Full Text] [Related]
39. Construction of an initial microRNA regulation network in breast invasive carcinoma by bioinformatics analysis. Yin Y; Shen C; Xie P; Cheng Z; Zhu Q Breast; 2016 Apr; 26():1-10. PubMed ID: 27017236 [TBL] [Abstract][Full Text] [Related]
40. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Hu Y; Xu K; Yagüe E Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]